Feyruz V. Rassool

University of Mary — United States

Medicine · Health Sciences

40h-index5.5kcitations241works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(69), DNA Repair Mechanisms(64), Chronic Myeloid Leukemia Treatments(61), PARP inhibition in cancer therapy(56), Epigenetics and DNA Methylation(26)

Publications241 total

Next generation sting agonist in combination with DNA methyltransferase inhibitors induce an apoptotic cell death mechanism driven by apoptosis in TP53-mutated Acute Myeloid Leukemia
Blood·2025Open Access
Abstract A069: Epigenetic reprogramming restores STING pathway activation in high-grade serous ovarian cancer
Cancer Research·2025
Abstract B009: BRCA1 regulates ZNFX1-induced mitochondrial dysfunction and STING activation in high grade serous ovarian cancer
Cancer Research·2025
A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
2025Open Access
Abstract P1-09-16: A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer and non-mutated BRCA
Clinical Cancer Research·2025
Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer
Cancer Research·2025· 5 cited
Abstract CT191: Intravenous infusion of the allosteric small molecule STING agonist CRD3874-SI in patients with relapsed or refractory acute myeloid leukemia: A phase I trial
Cancer Research·2025
The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer
Biomedicines·2025· 2 citedOpen Access
Abstract 1698: Synergy with decitabine expands the utility of talazoparib: A novel therapeutic strategy for BRCA-proficient pancreatic cancer
Cancer Research·2025
Abstract 5865: Novel allosteric STING agonists in combination with DNA methyltransferase inhibitors induce an interferon-driven apoptotic response in <i>TP53</i>-mutated acute myeloid leukemia
Cancer Research·2025
Abstract 4844: Epigenetic reprogramming of the STING pathway as a combination strategy in high grade serous ovarian cancer
Cancer Research·2025
Supplementary Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
2025Open Access
Data from ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
2025Open Access
Abstract PR001: ZNFX1 is a master regulator and tumor suppressor in epigenetically-induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer
Cancer Research·2025
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
Cancer Research·2025· 5 citedOpen Access
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer
2024Open Access
The Epigenetic Hallmarks of Cancer
Cancer Discovery·2024· 101 cited
Abstract 2838: ZNFX1 is a master regulator and tumor suppressor in epigenetically induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer
Cancer Research·2024
Abstract PR-005: ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells
Cancer Research·2024
Supplement Figure S1 from Aromatase Inhibitor–Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Carine Robert(9), Stephen B. Baylin(9), Pratik Nagaria(6), Terry J. Gaymes(6), Ghulam J. Mufti(6), Jinshui Fan(4), Limin Xia(4), Maria R. Baer(4), Rena G. Lapidus(4), S. Tiong Ong(4), Alan E. Tomkinson(4), Timothy W. McKeithan(4), Yi Cai(3), Annahita Sallmyr(3), Donald Small(3), Nidal Muvarak(3), Eun Yong Choi(3), Nicola Brady(3), Michelle M. Le Beau(3), Aksinija A. Kogan(3)